Smoking does not appear to be a major cause of prostate cancer in the way it causes lung cancer, but it significantly increases the chance of dying from it. Current smokers face a 30% higher risk of fatal prostate cancer compared to men who have never smoked, and men who were still smoking within 10 years of their cancer death had roughly double the risk. The relationship between smoking and prostate cancer is less about whether you get it and more about how aggressively it behaves once it develops.
How Smoking Affects Prostate Cancer Risk
Prostate cancer is extremely common. About 1 in 8 men will be diagnosed with it during their lifetime, and most of those cases have nothing to do with tobacco. Smoking contributes to roughly 3% of global prostate cancer deaths, a small fraction compared to its role in lung or bladder cancer. But that modest-sounding percentage masks what smoking actually does: it shifts the odds toward more dangerous, harder-to-treat disease.
Studies consistently show that smokers are more likely to be diagnosed with higher-grade tumors and more advanced stages of prostate cancer. The cancer tends to be more aggressive at the time it’s found. Smoking is also linked to a higher likelihood of the cancer spreading, recurring after treatment, and becoming resistant to hormone therapy. In the Health Professionals Follow-Up Study, which tracked over 5,000 men diagnosed with prostate cancer, those who were smoking at the time of diagnosis had an 82% higher risk of dying from their cancer compared to men who had never smoked.
Why Tobacco Is Harmful to the Prostate
Cigarette smoke delivers dozens of cancer-causing chemicals into the bloodstream, including compounds that can directly damage DNA in cells throughout the body. Two groups are especially relevant to the prostate: polycyclic aromatic hydrocarbons and nitrosamines, both of which are well-established carcinogens. But the chemical that stands out for prostate health specifically is cadmium, a heavy metal found in cigarettes.
Cadmium doesn’t cause cancer in the prostate through direct genetic mutations the way many carcinogens work. Instead, it mimics testosterone. The prostate is a hormone-sensitive organ, and its cells have receptors that respond to testosterone to regulate growth. Cadmium binds to those same receptors and amplifies their activity, essentially tricking prostate cells into behaving as though they’re receiving stronger hormonal signals than they actually are. In cancer cells, this accelerated hormonal response can fuel growth and progression.
Smoking also drives chronic inflammation, which is now recognized as a key factor in how cancers develop and spread. In prostate cancer patients who smoke, inflammatory markers are significantly elevated, particularly in men with advanced-stage disease. This persistent inflammation promotes genetic instability in cells, supports tumor growth, helps tumors develop their own blood supply, and aids the cancer’s ability to invade surrounding tissue.
Smoking Can Mask Early Warning Signs
One of the more troubling findings about smoking and prostate cancer involves PSA, the blood test most commonly used to screen for the disease. Smokers actually have lower PSA levels than nonsmokers. Total PSA runs about 8% lower in current smokers and 12% lower in former smokers compared to men who have never smoked.
This means that men who smoke are less likely to trigger an abnormal PSA result, which in turn makes them less likely to be referred for a biopsy. The cancer may go undetected for longer, giving it more time to grow and potentially spread before it’s caught. This delayed detection likely contributes to the pattern of smokers being diagnosed with more advanced disease and having worse outcomes overall. It’s a compounding problem: smoking makes the cancer more aggressive while simultaneously making it harder to find early.
What Happens After Treatment
Smoking doesn’t just affect the initial diagnosis. It continues to influence outcomes after treatment. Men who smoke at the time of diagnosis face higher rates of biochemical recurrence, which is when PSA levels begin rising again after surgery or radiation, signaling that cancer cells are still active or have returned. Smokers are also more likely to develop metastatic disease after treatment and to progress to hormone-resistant cancer, which is much more difficult to manage.
These effects appear to be driven by the same mechanisms at work before diagnosis: ongoing DNA damage from tobacco chemicals, inflammatory signaling that supports tumor survival, and cadmium’s interference with hormone pathways that treatment is trying to control.
Quitting Reverses Much of the Risk
The most actionable finding in this research is how dramatically quitting changes the picture. Men who stopped smoking 10 or more years before their prostate cancer diagnosis had mortality risks essentially identical to men who never smoked. Their risk of the cancer recurring was also comparable to never-smokers.
Even men who quit less than 10 years before diagnosis saw benefits, particularly if they had a lighter smoking history (fewer than 20 pack-years, which is roughly a pack a day for 20 years or half a pack for 40 years). Their prostate cancer death risk dropped to levels statistically similar to never-smokers as well. The 10-year mark appears to be the threshold where the prostate largely recovers from smoking’s effects, at least in terms of cancer-specific survival. Current smokers, by contrast, had the worst outcomes across every measure: overall mortality, cancer-specific mortality, cardiovascular death, and recurrence.
For men already diagnosed with prostate cancer, quitting at the time of diagnosis still matters. The data consistently show that continuing to smoke after diagnosis worsens every outcome that can be measured. The benefits of cessation accumulate over time, and the sooner it happens, the better the trajectory.